🎉 M&A multiples are live!
Check it out!

Leap Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Leap Therapeutics and similar public comparables like Pharming, Benevolent AI, and Galapagos.

Leap Therapeutics Overview

About Leap Therapeutics

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .


Founded

2011

HQ

United States of America
Employees

52

Website

leaptx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$32.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Leap Therapeutics Financials

Leap Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Leap Therapeutics achieved revenue of n/a and an EBITDA of -$70.1M.

Leap Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Leap Therapeutics valuation multiples based on analyst estimates

Leap Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$81.4M -$70.1M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$54.6M -$81.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Leap Therapeutics Stock Performance

As of April 15, 2025, Leap Therapeutics's stock price is $0.

Leap Therapeutics has current market cap of $14.1M, and EV of -$32.9M.

See Leap Therapeutics trading valuation data

Leap Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$32.9M $14.1M XXX XXX XXX XXX $-1.58

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Leap Therapeutics Valuation Multiples

As of April 15, 2025, Leap Therapeutics has market cap of $14.1M and EV of -$32.9M.

Leap Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Leap Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Leap Therapeutics and 10K+ public comps

Leap Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$32.9M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.5x XXX XXX XXX
P/E -0.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Leap Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Leap Therapeutics Valuation Multiples

Leap Therapeutics's NTM/LTM revenue growth is n/a

Leap Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Leap Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Leap Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Leap Therapeutics and other 10K+ public comps

Leap Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -14% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Leap Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Leap Therapeutics M&A and Investment Activity

Leap Therapeutics acquired  XXX companies to date.

Last acquisition by Leap Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Leap Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Leap Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Leap Therapeutics

When was Leap Therapeutics founded? Leap Therapeutics was founded in 2011.
Where is Leap Therapeutics headquartered? Leap Therapeutics is headquartered in United States of America.
How many employees does Leap Therapeutics have? As of today, Leap Therapeutics has 52 employees.
Who is the CEO of Leap Therapeutics? Leap Therapeutics's CEO is Mr. Douglas E. Onsi.
Is Leap Therapeutics publicy listed? Yes, Leap Therapeutics is a public company listed on NAS.
What is the stock symbol of Leap Therapeutics? Leap Therapeutics trades under LPTX ticker.
When did Leap Therapeutics go public? Leap Therapeutics went public in 2014.
Who are competitors of Leap Therapeutics? Similar companies to Leap Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Leap Therapeutics? Leap Therapeutics's current market cap is $14.1M
Is Leap Therapeutics profitable? Yes, Leap Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.